Kai Ma

First-line sugemalimab plus chemotherapy for metastatic non-small-cell lung cancer: an updated cost-effectiveness analysis based on 4-year survival data

OBJECTIVE: Incorporating the 4‑year long‑term survival outcomes from the GEMSTONE‑302 trial, this study aimed to evaluate the cost‑effectiveness of sugemalimab plus chemotherapy versus chemotherapy alone as first‑line treatment for metastatic non‑small‑cell lung cancer (NSCLC) fr...